Enliven Therapeutics to Present at Upcoming Investor Conferences
Enliven Therapeutics to Present at Upcoming Investor Conferences
PR Newswire
BURLINGAME, Calif., Sept. 3, 2026
BURLINGAME, Calif., Sept. 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in the following investor conferences:
Wells Fargo 21st Annual Healthcare Conference
Date: Tuesday, Sept. 8, 2026
Location: Boston, MA
Forum: 1x1 Meetings
Baird 2026 Global Healthcare Conference
Date: Tuesday, Sept. 15, 2026
Location: New York, NY
Forum: Fireside Chat and 1x1 Meetings
Morgan Stanley 24th Annual Global Healthcare Conference
Date: Wednesday, Sept. 16, 2026
Location: New York, NY
Forum: Fireside Chat and 1x1 Meetings
A live webcast of the Morgan Stanley fireside chat will be available in the Investor Relations section of the Company's website at https://ir.enliventherapeutics.com/. A replay of the webcast will be archived on the Company's website for 90 days following the conclusion of the presentation.
About Enliven Therapeutics
Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision medicine approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights into clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. To learn more, visit www.enliventherapeutics.com and connect with us on LinkedIn and X.
SOURCE Enliven Therapeutics, Inc.
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States